Editor’s Note: Another in the series on the people behind Genesis, this one from the clinical side. It is built from Dr. Fedder's professional record and public reporting.
Every medical device company eventually runs into a question it can't answer from the inside: would a surgeon actually use this? The answer decides whether a product earns a place in the operating room, and it almost never comes from the company that built it.
Dr. Ira Fedder spends his working life on the other side of that question. He is a fellowship-trained orthopaedic spine surgeon with more than 35 years of clinical experience, a Genesis member and part of the medical advisory board behind Genesis MedTech.
His practice covers operative and non-operative care of spine and neck conditions, so he sees the full range of options a patient has, which is exactly the context any new device has to compete in. That breadth matters in a device conversation, because a surgeon's day is made of trade-offs, and a product is judged against them. Public reporting has described his clinical focus as including cervical disc herniation, myelopathy, cervical stenosis, lumbar stenosis and sciatica. He is affiliated with University of Maryland St. Joseph Medical Center in Towson, Maryland, and has been named a Top Doctor in Spine Surgery by Baltimore magazine.
He has also advised a device company directly. Becker's Spine Review reported in 2013 that Tyber Medical, a New Jersey medical device company, added him as a surgeon advisor. For a founder, that kind of experience is practical, and here is why.
A clinical advisor can answer what engineers and investors can't. Where in the procedure does this device sit? What does it replace, and what would make a surgeon change a technique they have used for years? What evidence would a colleague need to see before trying it? Those are the questions a hospital committee will ask, and a founder who has already heard them from a practicing surgeon can answer them calmly.
That matters because hospitals don't buy on regulatory clearance alone. A value analysis committee of clinical and administrative staff reviews each new product. Clinicians assess how it would be used, and administrators weigh the cost against clinical, patient and process outcomes. So clinical credibility sits right in the middle of the purchasing decision, and a founder whose product has never faced a practising surgeon's questions meets them for the first time in front of the committee.
Reimbursement raises the stakes. A hospital can only use what it can be paid for, and if no suitable billing code exists, the application for a new CPT code can take up to 24 months. How clinicians describe a procedure, and where a device fits inside it, shapes how that case gets built.
The same goes for investors reading a medical deal. It is easy to tell a clinical story and much harder to test one. Claims about clinical benefit sound equally confident in every pitch, and the people best placed to test them are the ones who treat patients. A board of working clinicians gives a medical company a way to check its clinical story before capital or customers depend on it.
That is the job of the advisory board at Genesis MedTech, a co-ordinated market entry programme for medical device, health-tech and software companies that takes them from first market assessment to first signed contract. Alongside the partners, six practising physicians and clinical leaders help shape how each product is positioned for clinical adoption, reimbursement alignment and health system credibility. Dr. Fedder's spine expertise is one part of a board that spans pain medicine, internal medicine and nephrology, dentistry and orthopedic spine surgery.
The partners bring the commercial side: group purchasing organisation relationships, health system contracting and enterprise sales experience. The advisory board brings the clinical side, which is the half a founder is least likely to have in house. You need both, because a product can satisfy a purchasing contract and still fail to win a surgeon's confidence, or win the surgeon and stall at purchasing.
For a founder, that means physicians with decades in practice can look at how your product is positioned before it meets a hospital committee. For an investor, it is a reason to trust that the clinical case behind a medical company has been looked at by people who treat patients. If you are building a medical device, health-tech or software company and want that perspective on your US plans, write to the Genesis team at amiel@genesisbh.net or ranny@genesisbh.net, or visit www.genesisbh.net. A short note about the product and the stage it has reached is enough to start.